Background The risk of cancer treatment‐related acute exacerbation (AE) in patients with
lung cancer and mild interstitial lung disease (ILD) on imaging, classified as indeterminate …

Purpose To characterize pulmonary toxicities associated with the use of novel immune
checkpoint inhibitors Methods Adverse event reports from immune checkpoint inhibitors …

Interstitial lung abnormalities (ILAs) are incidentally found nondependent parenchymal
abnormalities affecting more than 5% of any lung zone and are potentially related to …

Interstitial lung abnormalities (ILAs) are radiologic abnormalities found incidentally on chest
computed tomography (CT) that can be show a wide range of diseases, from subclinical …

Patients with interstitial lung disease (ILD), especially those with idiopathic pulmonary
fibrosis, are at increased risk of developing lung cancer (LC). Pharmacotherapy for …

Interstitial lung abnormalities (ILA) is a radiographic term, which has recently undergone
clarification of definition with creation of 3 subtypes. ILA is defined as incidental identification …

Background Drug-induced pneumonia, especially immune-related adverse events, can
sometimes be fatal, and it is crucial to seize the signs for early treatment. A clinical trial …

Introduction Interstitial lung disease (ILD) is a known risk factor for lung cancer (LC).
However, the surgical risk of LC in patients with ILD remains unclear. Therefore, we …

Background In patients with non‐small cell lung cancer (NSCLC), interstitial lung
abnormalities (ILA) have been linked to mortality and can be identified on computed …

Summary Introduction/Background Durvalumab demonstrated a good efficacy and safety in
patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent …